



## **Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference**

September 10, 2021 at 7:00 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 10, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will present at the H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference, being held from September 13-15, 2021.

The pre-recorded presentation will be made available for on-demand viewing starting Monday, September 13, 2021 at 7:00 a.m. ET on the Company's website, [www.precisionbiosciences.com](http://www.precisionbiosciences.com), in the Investors & Media section under Events and Presentations. An archived replay of the webcast will be available for approximately 90 days.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).



View source version on [businesswire.com](https://www.businesswire.com/news/home/20210910005202/en/): <https://www.businesswire.com/news/home/20210910005202/en/>

### **Investor Contact:**

Alex Kelly  
Chief Financial Officer  
[Alex.Kelly@precisionbiosciences.com](mailto:Alex.Kelly@precisionbiosciences.com)

### **Media Contact:**

Maurissa Messier  
Senior Director, Corporate Communications  
[Maurissa.Messier@precisionbiosciences.com](mailto:Maurissa.Messier@precisionbiosciences.com)

Source: Precision BioSciences, Inc.